There is a titration period of about six weeks ... to discuss the early days of the launch and a few performance indicators that we plan to provide for the next several quarters to assist you ...

The company remains vigilant about potential generic competition for Auryxia and is focused on advancing its HIF-PH inhibitor pipeline. While analysts don’t expect profitability this year, with a ...

Liquidia Technologies Inc. (NASDAQ:LQDA) reported a larger net loss for Q1 2025 compared to the previous year, despite a slight increase in revenue. The company’s earnings per share (EPS) fell short ...

Liquidia Technologies Inc. (NASDAQ:LQDA) reported a larger net loss for Q1 2025 compared to the previous year, despite a slight increase in revenue. The company’s earnings per share (EPS) fell ...

All projections presented were prepared in April 2025. 1 Shows data from the IMF Country Report 24/90 issued on March 1, 2024. 2 The acceleration in GDP growth in 2024 is due to the start of ...

The Pacific Islands are vulnerable to natural disasters, climate change, commodity price changes, and uncertain donor grants. The question that arises is how should small developing countries ...

Zealand Pharma (ZEAL) reported its financial results for Q1 2025, highlighting a revenue of 8 million DKK, primarily driven by its Segalog license agreement with Novo Nordisk. The company anticipates ...